Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-231 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7504.091 | 0.9703 | 0.9700 | 1.9941 | |
| MDA-MB-231 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7504.091 | 0.9319 | 0.9305 | 1.9941 | |
| MDA-MB-231 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7504.091 | 0.9293 | 0.9278 | 1.9941 | |
| MDA-MB-231 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7504.091 | 0.9021 | 0.8993 | 1.9941 | |
| MDA-MB-231 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7504.091 | 0.8339 | 0.8259 | 1.9941 | |
| MDA-MB-231 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7504.091 | 0.5268 | 0.4502 | 1.9941 | |
| MDA-MB-231 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7504.091 | 0.0073 | -0.8306 | 1.9941 | |
| MDA-MB-231 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7504.091 | 0.0003 | -0.9636 | 1.9941 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7505.09 | 1.0452 | 1.1455 | 0.6295 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7505.09 | 0.9811 | 0.9403 | 0.6295 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7505.09 | 1.0585 | 1.1892 | 0.6295 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7505.09 | 0.9646 | 0.8887 | 0.6295 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7505.09 | 1.0305 | 1.0979 | 0.6295 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7505.09 | 0.9770 | 0.9275 | 0.6295 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7505.09 | 0.8285 | 0.4833 | 0.6295 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7505.09 | 0.7990 | 0.4003 | 0.6295 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7505.09 | 0.9644 | 0.8879 | 0.6295 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7506.091 | 0.9287 | 0.8710 | 1.1096 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7506.091 | 0.9658 | 0.9383 | 1.1096 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7506.091 | 0.9798 | 0.9636 | 1.1096 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7506.091 | 0.9024 | 0.8233 | 1.1096 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7506.091 | 0.9992 | 0.9985 | 1.1096 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7506.091 | 0.9223 | 0.8594 | 1.1096 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7506.091 | 0.7705 | 0.5812 | 1.1096 | |
| MDA-MB-361 | HER2amp | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7506.091 | 0.0189 | -0.9440 | 1.1096 |